A small panel of circulating biomarkers may reliably distinguish hypertrophic cardiomyopathy (HCM) from similar conditions that cause left ventricular hypertrophy (LVH), researchers found. From ...

New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten)SOUTH SAN FRANCISCO, ...

You can manage the risks of hypertrophic cardiomyopathy (HCM) with treatment and lifestyle changes. Here’s how to make the most of your next medical checkup. HCM is a genetic condition in which the ...

Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining ...

Hypertrophic cardiomyopathy (HCM) is often seen in patients as an autosomal dominant genetic heart disease with a variable clinical course. It is characterized by left ventricular hypertrophy, and ...

Genetic testing for hypertrophic cardiomyopathy (HCM) uses a blood sample to analyze DNA for disease-causing variants. Testing often includes genetic counseling and is best done at an HCM center. A ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

Novel mavacamten had a big impact on quality of life in obstructive hypertrophic cardiomyopathy, according to a secondary analysis of the EXPLORER-HCM trial. The cardiac myosin inhibitor improved ...

Fact checked by Jennifer Klump Meet the Author Christopher Lee, MD, is a board-certified cardiologist and internal medicine physician based in San Francisco, CA. He specializes in multimodality ...

After treating the local community for more than 30 years, Dr. Stephen Kemker became a patient himself ...